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Abstract
An integrated elastomeric microfluidic device, with a footprint the size of a postage stamp, has
been designed and optimized for multistep radiosynthesis of PET tracers.
Methods—The unique architecture of the device is centered around a 5-μL coin-shaped reactor,
which yields reaction efficiency and speed from a combination of high reagent concentration,
pressurized reactions, and rapid heat and mass transfer. Its novel features facilitate mixing, solvent
exchange, and product collection. New mixing mechanisms assisted by vacuum, pressure, and
chemical reactions are exploited.
Results—The architecture of the reported reactor is the first that has allowed batch-mode
microfluidic devices to produce radiopharmaceuticals of sufficient quality and quantity to be
validated by in vivo imaging.
Conclusion—The reactor has the potential to produce multiple human doses of 18F-FDG; the
most impact, however, is expected in the synthesis of PET radiopharmaceuticals that can be made
only with low yields by currently available equipment.
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The diagnostic power of PET (1) has been demonstrated in multiple fields including
oncology (2), neurology (3), cardiology (4), and inflammation (5). The advantages of PET
have also been realized in drug discovery (6–8). This technique exploits biomarkers that
contain positron-emitting radionuclides such as 18F, 11C, 13N, and 15O. Their short half-lives
place a significant constraint on the production of these biomarkers. Unlike other chemical
compounds (both drugs and contrast agents), PET probes have to be prepared hours or
minutes before injection and cannot be stored. Meanwhile, it is well known that multistep
chemical syntheses of many druglike compounds may take days.
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One way of overcoming this challenge is the design of synthetic routes such that the
radionuclide is incorporated in the last step or close to it. Most of the known probes (such
as 18F-FDG (9,10) and 3′-deoxy-3′-18F-fluorothymidine (11)) involve 2 synthetic steps that
are precluded by radioisotope concentration and followed by purification and formulation of
the injectable dose. Others (e.g., 2′-deoxy-2′-18F-fluoro-5-methyl-1-β-D-
arabinofuranosyluracil (12) or 18F-fluoroazomycin-arabinoside (13)) require longer
synthetic procedures that may limit their clinical use. The optimal radionuclide for use in
PET, 18F (with a half-life of 110 min), still limits the time for carrying out these processes
and delivery of the product to the patient to just a few hours. On top of the short time frame,
another challenge of radiosynthesis is the need for its remote manipulation because there has
to be a shield between the chemist and the source of radiation.
Over the years since the introduction of PET, multiple examples of such setups have been
shown ranging from user-designed systems (14) to commercially available completely
automated synthesis modules (ASMs) (15). Although some of these systems demonstrate
relative advantages over others, most rely on traditional chemist’s tools—glass flasks or
vials, heaters, and chromatography, which is designed for manipulating relatively large
amounts of chemicals and volumes of solvent measured in milliliters. Meanwhile, mass of a
PET tracer in a single human dose is measured in nanograms. For example, an 18F-FDG
patient dose measuring 740 MBq (20 mCi) contains only 300 ng of 18F-FDG (assuming
specific activity of 370 GBq/μmol [10 Ci/μmol]). Dissolving it in several milliliters of
solvent results in a low concentration. Although low mass is beneficial for reducing the toxic
effects in the patient, low concentration is generally known to reduce reaction rates and
increase synthesis times.
These observations have suggested that a dramatic increase in concentrations of reagents
during radiosynthesis should lead to improved effective yields, meaning more doses
available for patients at the end of synthesis. The limiting reagent in these radiosyntheses is
the radioisotope, and its amount cannot be increased to increase the concentration.
Therefore, reducing the volume of solution is the only way to attain a high concentration of
radioisotope. Volume reduction also leads to high concentrations generated with low
precursor amounts. Scaling the reaction volume down from milliliters to microliters makes it
impossible for the radioisotope to be handled by any of the reported ASMs without the risk
of losing the entire reaction mixture. This requirement for small-volume handling has turned
the attention to microfluidics.
Microfluidic devices are known for several advantages (16–18) that, if applied to the
synthesis of radiopharmaceuticals, could circumvent many of the existing limitations and
increase radiosynthesis output. Besides the concentration advantage, these devices promise
additional benefits derived from rapid mass and heat transfer.
18F-FDG (1) was chosen as a reference for comparing different methods because it is the
most widely used PET probe whose synthesis (Scheme 1) has had the most optimization on
conventional instruments. Starting with 18F-fluoride, the synthesis is based on the following
3 sequential processes: concentration of the 18F-fluoride from dilute 18O-H2O solution (1–
10 ppm) followed by drying, 18F-fluoride substitution reaction with the mannose triflate
(MT) precursor (2) using Kryptofix2.2.2 (Sigma-Aldrich) (3) phase transfer reagent to
allow 18F-KF solubility in anhydrous MeCN, and aqueous acidic hydrolysis of the
fluorinated intermediate tetraacetylated 18F-fluoroglucose compound (18F-FTAG) (4).
Traditionally, microfluidic devices rely on reactions performed in moving solutions. Several
groups have applied such an approach (19,20) in radiosynthesis of PET probes (most
commonly 18F-FDG). Most such devices have demonstrated high yields of individual steps.
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However, all of them relied on macroscopic batch methods for the first process (fluoride
concentration, drying, and solvent exchange), and it is difficult to bridge the resulting
macro–micro gap without significant material losses. Microfluidic flow-through methods for
fluoride concentration are just at a conception stage (21). Also, extremely low volumes
(such as 5 μL) cannot be handled by continuous-flow devices without significant sacrifice of
material, meaning that the full advantage of extreme concentrations cannot be realized.
An alternative microfluidic approach relies on a batch mode of operation in all steps and
requires efficiency of material transfer. This alternative approach is based on a technology
termed chemical reaction circuit (CRC), which involves multilayer integrated elastomeric
microfluidics (22) performing unit operations. The first such device has been produced by
Lee et al. (23), who demonstrated that indeed all operations starting with 18F-fluoride
in 18O-H2O and yielding 2.15 MBq (58 μCi) of 18F-FDG can be performed on a single chip.
Although that was a major step forward in this area, it again had a micro–macro disconnect
hidden in the time it would take the on-chip trap to process 2 mL of 18O-H2O (4.6 d at a
reported 5 nL/s) through the on-chip column constructed using sieve valves.
Lessons learned from this work have led to the device reported here. Fundamentally
different from the first CRC, the current device is designed to allow a 1,500-fold increase in
throughput (up to ~3.7 GBq [100 mCi]) while ensuring seamless integration of all
radiosynthesis steps that take the user from raw isotope to purified product. The key features
of this chip include a relatively large (for microfluidics) coin-shaped reaction chamber and a
vacuum vent (Fig. 1). The first prototype chip with these features has been described briefly
in the supporting online material provided by Lee et al. (23). Although that prototype chip
relied on inferior mixing processes and did not have the entire radiosynthesis integrated, it
has effectively yielded the first published preclinical PET image obtained with a product of
a microfluidic device. Design, analysis, and optimization of the coin-shaped reactor chips
(Figs. 2 and 3) and their operation are the focus of this article.
MATERIALS AND METHODS
Materials
Solvents, acetonitrile (Riedel-deHaën), and water (Fisher Scientific) were used without
further purification. MT (ABX) was used as a solution in dry MeCN (25 mg/mL), which
was prepared immediately before each experiment using dry glassware flushed with N2.
Kryptofix2.2.2 solution in MeCN (50 mg/mL) was prepared weekly and stored at +4°C
when not in use. A cyclotron (Eclipse HP; Siemens) was used to produce no-carrier-
added 18F-fluoride (specific activity, >370 GBq/μmol [10 Ci/μmol]) by 11-MeV proton
bombardment of 95% 18O-enriched H2O via 18O(p,n)18F nuclear reaction.
The CRC was made from commonly used polydimethylsiloxane using pneumatic push-up
valves (24). To avoid diffusion of N2 gas from control channels into flow channels through
the valve diaphragms, the control channels were filled with Krytox 100 (Dupont) fluorinated
oil that did not penetrate polydimethylsiloxane, even at elevated temperatures. After initial
tests, the valves were doubled to reduce their failure.
Device Fabrication
The devices were fabricated (Supplemental Fig. 1; supplemental materials are available
online only at http://jnm.snmjournals.org) using the soft-lithography method (25) within a
class 1,000 clean-room environment. Early CRCs were composed of 2 functional layers: a
flow layer containing the coin-shaped reactor and the network of channels and a control
layer that incorporated the valves and the radiator vent (placed below the reactor). A third
(blank) layer was used to ensure strong bonding of the device to the substrate. Further
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details are described in the supplemental materials. In the latest iterations, the vent was
placed above the reactor, requiring an additional layer. Such 4-layer chips with 3 functional
layers were fabricated at Fluidigm Corp. by a proprietary process.
Control Interface
Pneumatic operation of on-chip valves and reagent delivery was achieved by ultra-high-
purity N2 gas providing pressures of 276 MPa (40 psi) and 83 MPa (12 psi) to the control
and flow manifolds, respectively. These manifolds were controlled through a BOB3
breakout controller board (Fluidigm Corp.). Control and flow lines were connected to the
chip via hollow metal pins (23 gauge; New England Small Pin Corp.) and Tygon microbore
tubing (Cole-Parmer East). The closing of a microvalve was driven by the activation of a
channel in the manifold that pressurized the corresponding line of tubing. Banks of
solenoids controlling all pressures were operated via a LabVIEW program (National
Instruments).
Radiometric Analysis
The amounts of radioactive material were determined using a CRC-25R dose calibrator
(Capintec, Inc.). The compositions of radioactive reaction mixtures and purified products
were analyzed using thin-layer chromatography (TLC). The analyte was spotted on a silica
gel–coated plate, which was subsequently developed in a 95:5 MeCN:H2O solvent. On
development, TLC plates were analyzed with an AR-2000 radio-TLC imaging scanner
(Bioscan). TLC analysis of crude mixtures provided yield information, and that of purified
products led to the radiochemical purity.
In Vivo Imaging
The methods related to the tumor model we used have previously been published (23). In
brief, a nonmetastasizing retrovirally induced rhabdomyosarcoma was injected by
intramuscular inoculation, forming tumors in 7–10 d. In these immune-competent mice, the
tumors initiated a strong immune response before regression after 4–5 wk. The immune
response increased metabolism that can be observed using 18F-FDG PET studies.
The mouse was imaged for 15 min in a Siemens Focus 220 microPET 1 h after tail vein
injection of 13.9 MBq (375 μCi) of 18F-FDG, with images created at a 1.2-mm resolution
using maximum a posteriori reconstruction. Immediately after the PET scan, a 10-min CT
scan was acquired using a Siemens MicroCAT II small-animal CT system, using Feldkamp
reconstruction to create images with a 0.4-mm resolution. PET and CT images were
combined to make a fused coregistered image with AMIDE imaging software (26).
RESULTS
Ion Exchange Column and Reaction Chamber Design
The logic behind the new CRC (27) architecture was based on the requirement to process 2
mL of 18O-H2O (volume determined by cyclotron and target design) without a negative
effect on CRC operation time. An off-chip column operated by on-chip valves (Fig. 3A) was
considered for the radiosynthesis devices because it has a higher resin surface area per
solvent volume ratio, it can be packed more efficiently (not through the chip), and it does
not require sieve valves (which severely restrict the flow of solvent through on-chip
columns). An optimized column had a 2-μL volume of AG1-X8 (Bio-Rad) resin bed. It
trapped 99.5% of 32.4 GBq (876 mCi) of 18F− at a flow rate of 2 mL/min, of which 92.7%
was subsequently released with approximately 5 μL of 0.5 M K2CO3. To simplify the
design, increase the release pressure, and avoid metal contact surfaces in the 18F-fluoride
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line, chips have been later redesigned (Fig. 3B) to work with columns operated by off-chip
ultra-low-volume rotary loop valves (Rheodyne).
On the basis of these results, the microreactor was in turn designed with a matching volume.
A wide, flat disk shape (5-mm diameter, 255-μm height) was selected to maximize the
surface area of the floor for heat transfer and temperature homogeneity and the ceiling for
rapid escape of gas (Fig. 1). Short height ensures rapid thermal equilibration. The circular
shape allows efficient mixing and product removal and minimizes stagnation zones in
corners and pockets. Finally, such a shape provides a large circumference that can be used
for many inlet and outlet ports. This shape has led to the term coin-shaped reactor. The
architecture designed around this reactor can be seen in Figure 2 and the chip fabricated
according to this design in Figure 3. All flow channels connected to the reaction chamber
(except for the water channel discussed in the supplemental materials) were made 200 μm
wide and 45 μm tall, with valve overlap sections 250 μm wide. Valve membranes were
made 25 μm in thickness.
Serpentine Vent
The second important feature of our CRC is a serpentine-shaped multipurpose vent channel
placed above the reaction chamber and separated from it by a thin, gas-permeable membrane
(28). The multipurpose vent enables efficient reagent loading by providing an escape for the
initial trapped gas out of the chamber while retaining the liquid. Application of vacuum in
the vent allows vapor removal from the reactor and completely out of the chip while
retaining the nonvolatile residues during evaporation steps. Application of pressure inside
the vent during reaction steps further increases reaction rates and prevents unwanted solvent
evaporation. The optimized vent comprises a serpentine pattern of 250-μm-wide 100-μm-tall
channels separated from the reactor ceiling by a 50-μm gas-permeable polydimethylsiloxane
membrane.
Mixing Mechanisms and Product Elution
New mixing mechanisms had to be designed because, unlike the earlier CRC, the reactions
are not performed in channels in which mixing is ensured by pumping solutions through
them. Five different tactics described in detail in the supplemental materials were explored
to achieve mixing in the coin-shaped reactor. Although early experiments with colored
solutions showed a mixing advantage in all 5 cases, the ultimate test with the actual 18F-
FDG radiosynthesis indicated that only the 3 methods mentioned here have led to increased
product yields without negative side effects. Vacuum-assisted mixing accelerates the
incoming liquid by removing all gas from the reactor before the corresponding valve is
opened, resulting in instant lamination with the solution already in the reactor. The
chemically assisted process relies on vigorous outgassing of CO2 from an acid–base reaction
at the interface between 2 solutions, to produce swirling. And the third process drives the
mixing by pressurizing the reactor through the vent.
Efficiency or product elution is ensured by the difference in cross-sections between
incoming and exit channels and positioning of these channels tangentially to the reactor
circumference.
18F-FDG Radiosynthesis
In summary, the coin-shaped reactor chip is designed to draw its radiosynthesis advantages
over other reported devices from ultra-high reagent concentrations, pressurized reactions,
loss-free material transfers, rapid temperature control, efficient mechanisms of mixing,
solvent evaporation, product elution, and, most importantly, efficient integration of the
complete radiosynthesis process. Sequence of chip operations, automated by controlling
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fluid pathways using specific valves (identified by the valve number labels in Fig. 2) and
pressurizing the reagents, was designed in the following manner:
• Loading and concentrating 18F−. 18F-fluoride in a dilute 18O-H2O solution (2 mL)
is directed by opening valves 1 and 2 to allow flow through and trapping on ion
exchange column C1. This process takes 1–2 min when driven by 69 MPa (10 psi)
of N2 gas pressure.
• Eluting 18F−. 18F-fluoride is eluted by passing 5 μL of aqueous 0.5 M K2CO3
solution through C1 in the direction opposite to trapping (most of the 18F− leaves
the column without having to travel through its entire length). This solution is
directed to the reactor via open valves 3, 4, and 5 using a process called dead-end
filling (i.e., replacing the air inside the reaction vessel with solution having one
inlet and no open outlet channels). This is accomplished by displacing the air from
the reactor into the evacuated radiator vent through the thin, gas-permeable
polydimethylsiloxane membrane separating the vent from the chamber.
• Drying. All valves are closed and the water is completely evaporated into the vent
by heating the bottom of the reactor at 90°C while applying vacuum in the vent.
• Solubilization of 18F− in organic solvent. Krypto-fix2.2.2 is brought into the reactor
in MeCN solution (50 mg/mL) through valve 6 by dead-end filling. With all valves
closed, acetonitrile is evaporated at 65°C through the vacuum vent. Traces of water
are removed as an azeotrope leaving behind 18F-KF/Kryptofix2.2.2 complex (dry
enough without subsequent azeotropic evaporations required in other methods),
which can be redissolved in MeCN.
• Introduction of MT. MeCN solution of MT (25 mg/mL) is delivered via a single
channel through valve 7. Its redissolving of 18F-KF/Kryptofix2.2.2 residue is
ensured by vacuum-assisted mixing.
• Fluorination. Valve 7 is closed and the reactor is heated to 75°C to drive
fluorination to completion while evaporating most of the MeCN, thus super-
concentrating the reaction mixture. This forms the 18F-FTAG intermediate in 3
min.
• Acid hydrolysis. Three molar HCl enters the reactor through valve 8 by dead-end
filling and immediately engaging in chemically assisted mixing. After the reactor is
full, the valve is closed and the chip is heated at 75°C while pressure is applied in
the vent to drive forward the 18F-FDG–forming hydrolysis reaction by pressure-
assisted mixing for 2 min.
• 18F-FDG elution. 18F-FDG product is eluted through valve 10 by flushing of the
reactor with water entering through valve 9. Because the crude product mixture is
acidic after hydrolysis, a small amount of KHCO3 (3 M, 10 μL) is loaded into the
water line in front of the water. It reacts with the acid and ensures that the solution
is neutral for the purification step.
• 18F-FDG purification. Eluted 18F-FDG passes through an alumina purification
cartridge (C2), which removes both Kryptofix2.2.2 and unreacted 18F-F− to
generate pure 18F-FDG.
Although this process has been tested, several material incompatibility issues have been
discovered. Their discussion, solutions, and a modified process (Supplemental Fig. 2) are
described in the supplemental material.
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DISCUSSION
Several successful syntheses have delivered just over 100 MBq (3 mCi) of 18F-FDG with
yield calculated from 18F-fluoride available for reaction reaching 96%. Further details and
discussion are provided in the supplemental material. Higher-scale production will be
possible when polydime-thylsiloxane is replaced with a suitable new material that solves the
issues of 18F-fluoride loss in reaction with polydimethylsiloxane and instability under
aqueous basic conditions. Potentially suitable inert elastomers have been reported (29–31).
The time needed to complete all necessary processes leading to 18F-FDG is 14 min. The
purity of the product collected after being passed through the alumina column was 99.3%.
The 18F-FDG produced was considered sufficiently pure to perform small-animal PET (32).
Tumor-carrying mice were injected after the doses had been diluted with saline. Further
details are provided in the supplemental material. One of the small-animal PET/CT images
obtained is presented in Figure 4. The tumor is clearly visible in the brachial area,
confirming proper 18F-FDG action. The absence of bone uptake further illustrates the
chemical purity (confirming absence of 18F-fluoride). Even before the optimization
described in this study was completed, one of the earliest coin-shaped reactor chips had
generated the first reported small-animal PET image obtained with a product of a
microfluidic device (23).
To understand the advantage of the reported CRC, one can compare the results of our study
with the values corresponding to modern state-of-the-art 18F-FDG production in a
commercial ASM such as Explora FDG4 (33), which has a run time of 45 min and average
decay-corrected yield of 75%. Radiochemical purity is similar (>99%). Reducing synthesis
time by 30 min increases the amount of 18F-based product in hand by about 20%, which can
equal to several patient doses at high scale (at 20 GBq, this means an extra 4 GBq, which
equals more than five 18F-FDG doses). This comparison demonstrates that the effective
yield is more influenced by the speed of the process than by the improvement in
radiochemical reaction yield.
CONCLUSION
After repeated successful demonstrations, the coin-shaped reactor chip architecture was
found suitable for robust production of multiple mouse doses of 18F-FDG. The only
obstacles preventing multiple human-scale dose production arise from the use of
polydimethylsiloxane as a chip material. Materials allowing the chip to retain integrity
during base handling and eliminating the 18F loss are under development: they should
enable a chip of the same fluidic design to produce multiple human doses of PET probes in a
matter of minutes by coupling improved robustness and elimination of 18F loss with high
yields, which were demonstrated by the chip reported in this article. Such improved chips
should lead to compact and flexible radiosynthesis instruments. Beyond 18F-FDG, they hold
more promise for the production of those PET probes that are known for their lengthy
syntheses and resulting low effective yields that jeopardize the delivery of multiple patient
doses. Another benefit of the new reactor will be realized in research and development of
new tracers capitalizing on higher efficiencies of reaction (due to high concentrations and
pressure) and shorter operation times (arising from fast reactions and solvent evaporations
granted by a more than 100-fold reduction in solvent volumes). The research setting may
benefit from either reusable chips with rapid cleaning cycles or disposable chips with easy
exchange mechanisms. Currently, the major limitation in PET is the lack of
radiopharmaceutical blockbusters. The chip technology that enables radiopharmaceutical
research as described by this study should accelerate the discovery of such compounds and
thus is critical for the future of PET. Finally, such reactors can have a significant impact on
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the drug discovery process, allowing drug candidates to be labeled and studied in vivo (7,8)
in a semihigh-throughput mode.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1.
Schematic of coin-shaped reactor designed for maximum heat and mass transfer, efficient
evaporation, and convenient placement of ports.
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FIGURE 2.
Complete design of coin-shaped reactor chip. C1 is ion exchange column, and C2 is product
purification column, both located off-chip. Reagents are introduced or removed through
indicated channels, via open valves 1–10. Radiator vent is shown in yellow. Light green
square outlines physical boundaries of chip. K222 = Kryptofix2.2.2.
Elizarov et al. Page 11
J Nucl Med. Author manuscript; available in PMC 2010 December 9.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIGURE 3.
(A) Photograph of chip with off-chip ion exchange column (C1) controlled by on-chip
valves. (B) Photograph of chip designed for coupling with off-chip ion exchange column
operated by off-chip loop valve. Chip is filled with dyes for visualization. Fluid network is
shown in green, valves in red, and vent in yellow.
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FIGURE 4.
PET image of tumor-bearing mouse.
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SCHEME 1.
Radiosynthesis of 18F-FDG (1).
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